Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1574-1579

  Korjamo, Timo ^a   Kemiläinen, Heidi ^a   Heikkinen, Aki T ^a   Mönkkönen, Jukka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; QUINIDINE;

ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIMULATION; TRANSCYTOSIS; TRANSPORT KINETICS;

ALGORITHMS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIMALARIALS; CACO-2 CELLS; CARRIER PROTEINS; CELL LINE; COMPUTER SIMULATION; DIGOXIN; DOGS; HUMANS; KINETICS; MODELS, STATISTICAL; P-GLYCOPROTEIN; PERMEABILITY; QUINIDINE;

EID: 34548061896     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016014     Document Type: Article

References (31)

1. Balakrishnan A, Hussainzada N, Gonzalez P, Bermejo M, Swaan PW, and Polli JE (2007) Bias in estimation of transporter kinetic parameters from over-expression systems: interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther 320:133-144.
2. m. Pharm Res 22:1667-1677.
3. Bergström CA, Strafford M, Lazorova L, Avdeef A, Luthman K, and Artursson P (2003) Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558-570.
4. Boulton DW, DeVane CL, Liston HL, and Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163-169.
5. Döppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, and Spahn-Langguth H (1999) Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther 288:348-357.
6. Gao J, Murase O, Schowen RL, Aube J, and Borchardt RT (2001) A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18:171-176.
7. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, and Friedberg T (2002) Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-1578.
8. González-Alvarez I, Fernandez-Teruel C, Garrigues TM, Casabo VG, Ruiz-Garcia A, and Bermejo M (2005) Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica 35:1067-1088.
9. Hidalgo IJ (2001) Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 1:385-401.
10. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson JE (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1334-1341.
11. Horie K, Tang F, and Borchardt RT (2003) Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res 20:161-168.
12. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
13. Irie M, Terada T, Tsuda M, Katsura T, and Inui K (2006) Prediction of glycylsarcosine transport in Caco-2 cell lines expressing PEPT1 at different levels. Pflugers Arch 452:64-70.
14. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, and Koren G (1999) Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol 277:F84-F96.
15. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276.
16. Karlsson J and Artursson P (1991) A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int J Pharm 71:55-64.
17. Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ, and Mönkkönen J (2005) Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 26:266-279.
18. Korjamo T, Mönkkönen J, Uusitalo J, Turpeinen M, Pelkonen O, and Honkakoski P (2006) Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm Res 23:1991-2001.
19. Kuh HJ, Jang SH, Wientjes MG, and Au JL (2000) Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther 293:761-770.
20. Kwon H, Lionberger RA, and Yu LX (2004) Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol Pharm 1:455-465.
21. Lowes S, Cavet ME, and Simmons NL (2003) Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 458:49-56.
22. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. (2004) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101:3569-3574.
23. Palmgrén JJ, Monkkonen J, Korjamo T, Hassinen A, and Auriola S (2006) Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 64:369-378.
24. Soldner A, Benet LZ, Mutschler E, and Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 129:1235-1243.
25. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, and Warhurst G (2001) Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584-591.
26. Troutman MD and Thakker DR (2003) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209.
27. a. J Pharmacol Exp Ther 314:391-399.
28. Willmann S, Schmitt W, Keldenich J, Lippert J, and Dressman JB (2004) A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031.
29. Winne D (1977) Correction of the apparent Michaelis constant, biased by an unstirred layer, if a passive transport component is present. Biochim Biophys Acta 464:118-126.
30. Yu LX and Amidon GL (1999) A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.
31. Zhang Y and Benet LZ (1998) Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res 15:1520-1524.